Advertisement

Digestive Diseases and Sciences

, Volume 33, Issue 2, pp 209–216 | Cite as

Gastric motility is an important factor in the pathogenesis of indomethacin-induced gastric mucosal lesions in rats

  • Shigeru Ueki
  • Koji Takeuchi
  • Susumu Okabe
Original Articles

Abstract

Effects of atropine, cimetidine, and 16,16-dimethyl prostaglandin E2 (16,16-dmPGE2) on indomethacin-induced gastric lesions were investigated in rats by correlating their effects on gastric acid and HCO}-3 secretion and motility. Subcutaneously administered indomethacin (25 mg/kg) produced gastric mucosal lesions within 4 hr. In parallel studies, an equivalent dose of indomethacin inhibited gastric HCO}-3 secretion, and stimulated gastric motor activity measured as intraluminal pressure recordings, whereas acid secretion was unaffected. The lesions induced by indomethacin were significantly prevented by three agents: cimetidine (100 mg/kg), which reduced acid secretion; atropine (1 mg/kg), which reduced acid secretion and gastric motility; and 16,16-dmPGE2 (10 μg/kg), which reduced acid secretion and motility and increased gastric HCO3 secretion. If acid (150 mM HCl) was infused into the stomach (1.2 ml/hr) during indomethacin treatment, only the latter two agents significantly prevented the formation of gastric lesions in response to indomethacin. Since only the effect on gastric motility was common to these two agents (atropine and 16,16-dmPGE2), the increased gastric motility may be an important pathogenetic factor in indomethacin-induced gastric lesions. The presence of acid as well as a deficiency of endogenous PGs may be prerequisite for later extension of the lesions but cannot account for the induction of mucosal lesions in rats following administration of indomethacin.

Key words

indomethacin gastric lesion acid motility rat 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Djahanguiri B: The production of acute gastric ulceration by indomethacin in the rat. Scand J Gastroenterol 4:265–267, 1969PubMedGoogle Scholar
  2. 2.
    Lanza FL: Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other nonsteroidal antiinflammatory agents. Am J Med 13:19–24, 1984Google Scholar
  3. 3.
    Lippman W: Inhibition of indomethacin-induced gastric ulceration in the rat by perorally administered synthetic and natural prostaglandin analogues. Prostaglandins 7:1–9, 1974PubMedGoogle Scholar
  4. 4.
    Kasuya Y, Urushidani T, Okabe S: Effects of various drugs and vagotomy on indomethacin-induced gastric ulcers in the rat. Jpn J Pharmacol 29:670–673, 1979PubMedGoogle Scholar
  5. 5.
    Robert A: Prostaglandins and the gastrointestinal tract.In Physiology of the Gastrointestinal Tract. LR Johnson, J Christensen, MI Grossman, ED Jacobson, SG Schultz (eds). New York, Raven Press, 1981, pp 1407–1434.Google Scholar
  6. 6.
    Whittle BJR: Temporal relationship between cyclooxygenase inhibition, as measured by prostacyclin biosynthesis, and the gastrointestinal damage induced by indomethacin in the rat. Gastroenterology 80:94–98, 1981PubMedGoogle Scholar
  7. 7.
    Takeuchi K, Ueki S, Okabe S: Importance of gastric motility in the pathogenesis of indomethacin-induced gastric lesions in rats. Dig Dis Sci 31:1114–1122, 1986PubMedGoogle Scholar
  8. 8.
    Takeuchi K, Ohtsuki H, Okabe S: Mechanisms of protective activity of 16, 16-dimethyl PGE2 and acetazolamide on gastric and duodenal lesions in rats. Dig Dis Sci 31:406–411, 1986PubMedGoogle Scholar
  9. 9.
    Dunnett CW: A multiple comparison procedure for comparing several treatments with a control. Am J Stat Assoc 50:1096–1121, 1955Google Scholar
  10. 10.
    Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nature (London), New Biol 231:232–235, 1971Google Scholar
  11. 11.
    Whittle BJR, Higgs GA, Eakins KE, Moncada S, Vane JR: Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 284:272–273, 1980Google Scholar
  12. 12.
    Ligmuski M, Golanska EM, Hansen DG, Kauffman GL: Aspirin can inhibit gastric mucosal cyclo-oxygenase without causing lesions in rats. Gastroenterology 84:756–761, 1983PubMedGoogle Scholar
  13. 13.
    Mersereau WA, Hinchey EJ: Role of gastric mucosal folds in formation of focal ulcers in the rat. Surgery 91:150–155, 1982PubMedGoogle Scholar
  14. 14.
    Ohno T, Yamamoto K, Takeuchi K, Okabe S: Effects of 16,16-dimethyl prostaglandin E2 on the gastric mucosal cell damage induced by indomethacin in rats. Jpn J Pharmacol 43:213–220, 1987PubMedGoogle Scholar
  15. 15.
    Van Kofschoten J, Hagelen F, Hillen F, Jager LP, Zandberg P, Van Noordwijk J: Protective effects of prostaglandins against ulcerogenic activity of indomethacin during different stages of erosion development in rat stomach; role of acid and bicarbonate secretion. Dig Dis Sci 28:1127–1132, 1983PubMedGoogle Scholar
  16. 16.
    Garner A, Flemstrom G, Heylings JR: Effects of antiinflammatory agents and prostaglandins on acid and bicarbonate secretions in the amphibian-isolated gastric mucosa. Gastroenterology 77:457–461, 1979Google Scholar
  17. 17.
    Heylings JR, Garner A, Flemstrom G: Regulation of gastroduodenal HCO 3 transport by luminal acid in the frogin vitro. Am J Physiol 246:G235-G242, 1984PubMedGoogle Scholar
  18. 18.
    Mersereau WA, Hinchey EJ: Prevention of indomethacin-induced gastric hypercontractility; a mucosal protective mechanism of prostaglandin E2. Gastroenterology 78:1221, 1980 (abstract)Google Scholar
  19. 19.
    Mersereau WA, Hinchey EJ: Prevention of phenylbutazone ulcer in the rat by glucose; role of a glycoprivic receptor system. Am J Physiol 242:G429-G432, 1982PubMedGoogle Scholar
  20. 20.
    Takeuchi K, Nobuhara Y: Inhibition of gastric motor activity by 16,16-dimethyl prostaglandin E2; a possible explanation of cytoprotection. Dig Dis Sci 30:1181–1187, 1985PubMedGoogle Scholar
  21. 21.
    Fang WF, Broughton A, Jacobson ED: Indomethacin-induced intestinal inflammation. Am J Dig Dis 22:749–760, 1977PubMedGoogle Scholar
  22. 22.
    Ohtsuki H, Yamamoto O, Okabe S: Scanning electron microscopic studies of cytoprotection by 16-dmPGE2 on indomethacin-induced gastric and intestinal lesions in rats.In Mechanisms of Mucosal Protection in the Upper Gastrointestinal Tract. A Allen, G Flemstrom, A Garner, W Silen, LA Turnberg (eds). New York, Raven Press, 1984, pp 371–376Google Scholar
  23. 23.
    Ohno T, Uramoto H, Ishihara T, Okabe S: Effects of 16,16-dimethyl prostaglandin E2 on surface epithelial cell damage in the rat stomach induced by vagal nerve stimulation. Jpn J Pharmacol 43:429–439, 1987PubMedGoogle Scholar
  24. 24.
    Mersereau WA, Hinchey EJ: The role of mechanical factors in the genesis of gastric ulcers in the indomethacin-insulin treated rat. Dig Dis Sci 30:388, 1985 (abstract)Google Scholar
  25. 25.
    Mersereau WA, Hinchey EJ: Gastric EMG; A newin vivo monitor of prostaglandin synthesis during ulcerogenesis in the indomethacin-insulin rat model. Gastroenterology 90:1550, 1986 (abstract)Google Scholar
  26. 26.
    Kauffman GL, Aures D, Grossman MI: Intravenous indomethacin and aspirin reduce basal gastric mucosal blood flow in dogs. Am J Physiol 234:G131-G134, 1980Google Scholar
  27. 27.
    Rainsford KD: Microvascular injury during gastric mucosal damage by antiinflammatory drugs in pigs and rats. Agents Actions 13:5–6, 1983PubMedGoogle Scholar
  28. 28.
    Guth PH, Kozbur X: Microcirculatory and mast cell changes in restraint stress; role of gastric acid. Am J Dig Dis 14:113–117, 1969PubMedGoogle Scholar
  29. 29.
    Main IMH, Whittle BJR: Investigation of the vasodilator and antisecretory role of prostaglandins in the rat gastric mucosa by use of nonsteroidal antiinflammatory drugs. Br J Pharmacol 53:217–224, 1975PubMedGoogle Scholar
  30. 30.
    Bickel M, Kauffman GL: Gastric gel mucus thickness; effect of distention, 16,16-dimethyl prostaglandin E2 and carbenoxolone. Gastroenterology 80:770–775, 1980Google Scholar

Copyright information

© Plenum Publishing Corporation 1988

Authors and Affiliations

  • Shigeru Ueki
    • 1
  • Koji Takeuchi
    • 1
  • Susumu Okabe
    • 1
  1. 1.Department of Applied PharmacologyKyoto Pharmaceutical UniversityKyotoJapan

Personalised recommendations